Skip to main content

Table 2 CAR-T cell-related complications and management in the ICU

From: The use of ICU resources in CAR-T cell recipients: a hospital-wide study

N (%) or Median [IQR] Overall (n = 71)
Isolated cytokine release syndrome 33 (46%)
 Grade 1 10
 Grade 2 17
 Grade 3 6
Time between CRS and ICU admission (days) 2 [1–3]
Neurotoxicity 26 (37%)
 Grade 1 4/26 (15%)
 Grade 2 5/26 (19%)
 Grade 3 3/26 (11%)
 Grade 4 14/26 (54%)
 Time between ICU admission and worst neurotoxicity grade (days) 1 [0–1]
Documented bacterial infection 21 (30%)
 Site of infection
 Catheter-related infection 15/21 (71%)
 Digestive/biliary tract 4/21 (19%)
 Urinary tract 1/21 (5%)
 Unknown 1/21 (5%)
Bacteria
 Coagulase negative Staphylococcus 13
 Enterobacteriaceae 3
 Pseudomonas aeruginosa 1
 Enterococcus faecium 1
 Clostridium difficile 2
 Paracoccus yeei 1
Specific treatments
 Tocilizumab 49 (69%)
 Median dosage (mg) 800 [560–1480]
 Median number of injections 1 [1–2]
 Time between ICU admission and tocilizumab (hours) 5 [2–15]
 Steroids 40 (56%)
 Time between ICU admission and steroids (hours) 23 [5–34]
 Siltuximab 9 (12.6%)
 Anakinra 2 (2.8%)
Non-specific treatments in the ICU
 Fluid resuscitation at day 1 (mL) 500 [0–1750]
 Broad spectrum antibiotics 70 (98%)
 Vasopressors 20 (28%)
 Mechanical ventilation 4 (6%)
 Renal replacement therapy 1 (1.5%)
Outcome
 Death in the ICU 1 (1.5%)
 Death in the hospital 8 (12%)
 Death at last follow-up 26 (37%)
 Median follow-up (months) 6 [2–15]
  1. CRS cytokine release syndrome, ICU intensive care unit